Swissmedic

Type: Organization
Name: Swissmedic
First reported Apr 14 2014 - Updated Apr 14 2014 - 1 reports

Newron and Zambon seek marketing approval for Parkinson's drug from Swissmedic

Newron Pharmaceuticals S.p.A., an R&D company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., a pharmaceutical company, have announced the submission of the application for authorization for safinamide to Swissmedic. The submission ... [Published Individual.com - Apr 14 2014]
First reported Apr 09 2014 - Updated Apr 09 2014 - 1 reports

Newron, Zambon seek marketing nod for Parkinson’s disease drug, safinamide from Swissmedic

Newron Pharmaceuticals, a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., a pharmaceutical company strongly committed to the respiratory, primary care and CNS therapeutic areas, announced that the ... [Published PharmaBiz - Apr 09 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 1 reports

New results with NW-3509 presented at SIRS Conference

Details Category: Small Molecules Published on Tuesday, 08 April 2014 08:27 Hits: 18 Unique mechanism has potential to benefit poor responders to antipsychotics in patients with schizophreniaNW-3509 well tolerated and safe in Phase I trialNewron ... [Published PipelineReview - Apr 08 2014]
First reported Apr 07 2014 - Updated Apr 08 2014 - 3 reports

Newron Pharmaceuticals Release: Safinamide Application For Authorization Submitted To Swissmedic

– Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., a pharmaceutical company strongly committed to the respiratory, primary care and CNS therapeutic areas, ... [Published BioSpace - Apr 08 2014]
First reported Mar 20 2014 - Updated Mar 20 2014 - 2 reports

ThromboGenics' vitreomacular traction drug Jetrea gets approval in Switzerland

Belgium-based biopharmaceutical firm ThromboGenics has received approval from the Swiss Agency for Therapeutic Products, Swissmedic, for Jetrea (ocriplasmin) to treat adults with vitreomacular traction (VMT), including when associated with a macular hole ... [Published Pharmaceutical Technology - Mar 20 2014]
First reported Mar 19 2014 - Updated Mar 19 2014 - 1 reports

Swiss Agency approves ThromboGenics' Jetrea to treat vitreomacular traction

Swissmedic, the Swiss Agency for Therapeutic Products, has approved ThromboGenics' Jetrea (ocriplasmin) for the treatment of adults with vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 m ... [Published Pharmaceutical Business Review - Mar 19 2014]
First reported Mar 18 2014 - Updated Mar 18 2014 - 1 reports

Swiss among best for social indicators: OECD

OECD headquarters in Paris. Photo: OECDPublished: 18 Mar 2014 23:28 GMT+01:00Updated: 18 Mar 2014 23:28 GMT+01:00Swiss residents live longer than those in any other country in the Organization for Economic Co-operation and Development (OECD) and have ... [Published The Local Switzerland - Mar 18 2014]
First reported Mar 18 2014 - Updated Mar 18 2014 - 1 reports

ThromboGenics' JETREA Approved in Switzerland for the Treatment of Vitreomacular Traction

- ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that Swissmedic has approved JETREA ® (ocriplasmin) for the treatment of adults ... [Published FirstWord Pharma - Mar 18 2014]
First reported Mar 18 2014 - Updated Mar 18 2014 - 1 reports

THROMBOGENICS : acute; JETREA® Approved in Switzerland for the Treatment of Vitreomacular Traction

- ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that Swissmedic has approved JETREA® (ocriplasmin) for the treatment of adults ... [Published 4 Traders - Mar 18 2014]
First reported Mar 17 2014 - Updated Mar 18 2014 - 4 reports

Swiss economic growth to accelerate: forecast

Photo: Credit SuissePublished: 18 Mar 2014 09:52 GMT+01:00Updated: 18 Mar 2014 09:52 GMT+01:00Economic growth in Switzerland is expected to accelerate this year and next driven by a robust domestic economy and an improved climate in Europe and the rest ... [Published The Local Switzerland - Mar 18 2014]
First reported Mar 18 2014 - Updated Mar 18 2014 - 1 reports

Targeting the niche

NV-Logistics is still a young company, but has seen a remarkably fast development since being established. Thierry Moreno, founder and owner, spoke with ITJ editor-in-chief Christian Doepgen about his range of services, the international setup and alignment ... [Published Transport Journal - Mar 18 2014]
First reported Mar 17 2014 - Updated Mar 17 2014 - 1 reports

GlobalSubmit 2014 Released to U.S. Food & Drug Administration, Now Available to Industry

– GlobalSubmit Inc., a provider of end-to-end software and services solutions for delivering high-quality electronic submissions to regulatory authorities, announces that GlobalSubmit 2014 Version 8.0 is now available to industry and has been released ... [Published Prlog - Mar 17 2014]

Quotes

...covers the indications "safinamide as add-on therapy to a stable dose of a single dopamine agonist" in early Parkinson's disease patients and "safinamide as add-on therapy to levodopa alone or in combination with other Parkinson's disease treatments" in mid-to late stage Parkinson's disease pa-tients. The submission was made by Zambon, who will be the Authorization holder
"This latest approval confirms our strong belief that Jetrea, in time, will become the treatment of choice for the earlier treatment of patients with VMT" De Haes said
"Everybody, every family is concerned on the territories in Newfoundland, Labrador, Quebec and Nunavut" she told reporters on Monday
"She pleaded desperately to be returned to Japan for the sake of her infant children" he told the council

More Content

All (22) | News (22) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Newron and Zambon seek marketing approval for P... [Published Individual.com - Apr 14 2014]
Newron, Zambon seek marketing nod for Parkinson... [Published PharmaBiz - Apr 09 2014]
New results with NW-3509 presented at SIRS Conf... [Published PipelineReview - Apr 08 2014]
Newron Pharmaceuticals Release: Safinamide Appl... [Published BioSpace - Apr 08 2014]
Safinamide marketing application submitted to S... [Published Pharma Letter - Apr 07 2014]
Newron Pharmaceuticals : Safinamide Application... [Published 4 Traders - Apr 07 2014]
ThromboGenics' vitreomacular traction drug Jetr... [Published Pharmaceutical Technology - Mar 20 2014]
Swissmedic approves ThromboGenics' Jetrea for v... [Published PharmaBiz - Mar 20 2014]
Swiss Agency approves ThromboGenics' Jetrea to ... [Published Pharmaceutical Business Review - Mar 19 2014]
Swiss among best for social indicators: OECD [Published The Local Switzerland - Mar 18 2014]
ThromboGenics' JETREA Approved in Switzerland f... [Published FirstWord Pharma - Mar 18 2014]
THROMBOGENICS : acute; JETREA® Approved in Swit... [Published 4 Traders - Mar 18 2014]
Canada fights EU seal trade ban at WTO [Published The Local Switzerland - Mar 18 2014]
Swiss economic growth to accelerate: forecast [Published The Local Switzerland - Mar 18 2014]
Targeting the niche [Published Transport Journal - Mar 18 2014]
Heli-skiing guide and woman die in avalanche [Published The Local Switzerland - Mar 17 2014]
North Korea envoy walks out of UN rights council [Published The Local Switzerland - Mar 17 2014]
GlobalSubmit 2014 Released to U.S. Food & Drug ... [Published Prlog - Mar 17 2014]
Company 'imported three tonnes of steroids' [Published The Local Switzerland - Mar 17 2014]
GW Pharmaceuticals' multiple sclerosis drug Sat... [Published Pharmaceutical Business Review - Nov 28 2013]
GW Pharma's Sativex receives Swiss approval [Published PharmaBiz - Nov 28 2013]
Pfizer's Xeljanz receives global regulatory app... [Published PharmaBiz - Jul 16 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.